English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Familial Mediterranean fever (FMF) is an autosomal recessive disease characterized by recurrent episodes of fever and inflammation. Approximately 10% of patients are reported to be resistant or non-responsive to colchicine. We describe a case of a 30-year-old female patient with familial Mediterranean fever resistant to treatment with colchicine and lack of clinical response to Anakinra, successfully treated with Infliximab. Our case suggests that Infliximab, an anti-TNF antibody, may represent a safe and effective therapy for the treatment of colchicine-resistant FMF.

Successful Treatment of Familial Mediterranean Fever with Infliximab in a Colchicine Resistant Patient